



July 28, 2020

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : **Disclosure under Regulation 30 and 31 (A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**
Stock Code : **BSE – 539787, NSE – HCG**
Reference : **Outcome of the Board meeting intimated to the Stock Exchanges on July 28, 2020**

We wish to inform you that the Board of Directors of the Company (“Board”), at their meeting held on this day, July 28, 2020, inter alia, has considered and approved the following agenda:

1. Allotment of 2,95,16,260 (Two Crores Ninety Five Lakhs Sixteen Thousand Two Hundred and Sixty) equity shares of INR 10 each of the Company, for cash, at a price per share of INR 130 (including share premium of INR 120 per share) on preferential basis, to Aceso Company Pte. Ltd., 38 Beach Road, #29-11 South Beach Tower, Singapore 189767 (“Investor”). The said equity shares shall be listed on the National Stock Exchange of India Limited and BSE Limited and shall be locked in as specified under SEBI (ICDR) Regulations, 2018.
2. Allotment of 1,85,60,663 (One Crore Eighty Five Lakh Sixty Thousand Six Hundred Sixty Three) warrants (“Series A Warrants”) to the Investor, at a subscription price per warrant of Rs. 130 (“Warrant Issue Price”) on preferential basis, with a right to the Warrant Holder on exercise to apply for and be allotted 1 (One) Equity Share of the face value of INR 10 each of the Company (“Equity Shares”) at a premium of INR 120 (Indian Rupees One Hundred and Twenty) per share for each warrant, in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the Series A Warrants, or such longer period, if any, as may be permissible under applicable laws.
3. Subject to the necessary approvals from the Securities and Exchange Board of India (SEBI), Stock Exchanges and other appropriate statutory authorities and shareholders, as may be required, the re-classification of the status of the following promoters and promoter group members from “Promoter and Promoter Group Category” to “Public Category” of the Company:
 - (a) Dr Ganesh Nayak – Promoter;
 - (b) Dr Prakash Nayak – Promoter Group Member;
 - (c) Mr Pradeep Nayak – Promoter Group Member;
 - (d) Dr K.S. Gopinath – Promoter;
 - (e) Dr Srinivas K Gopinath – Promoter Group Member;
 - (f) Dr B.S. Ramesh – Promoter;
 - (g) Dr Sudha Venkatesh – Promoter Group Member;

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



- (h) Mr. Adarsh Ramesh – Promoter Group Member; and
 - (i) Dr M. Gopichand – Promoter.
4. Appointment of Mr. Siddharth Patel (DIN 07803802) as Additional Director (Non Independent and Non-Executive Director) and Nominee of the Investor on the Board of the Company, with effect from July 28, 2020, who shall be liable to retire by rotation.

Mr. Siddharth Patel is not debarred from holding the office of a Director by virtue of any SEBI order or any other authority.

Profile of Sidharth Patel

Siddharth is a Partner at CVC and joined in 2010. Siddharth was based in the London office for seven years in the global TMT team and, as of 2017, is based in Singapore where his responsibilities include CVC India office. Prior to joining CVC, he was with Apax Partners where he spent nine years in the technology and telecommunications team leading or co-leading transactions across the sector. Prior to Apax, he worked at Monitor Company. Siddharth's previous investment experience in healthcare includes TriZetto, a leading provider of healthcare software and services. Siddharth holds First Class MA and BA Degrees from the University of Oxford.

Siddharth is not related to any of the Directors/KMPs of the Company.

5. Appointment of Mr. Amit Soni (DIN 05111144) as Additional Director (Non Independent and Non-Executive Director) and a Nominee of the Investor on the Board of the Company, who shall be liable to retire by rotation.

Mr. Amit Soni is not debarred from holding the office of a Director by virtue of any SEBI order or any other authority.

Profile of Amit Soni

Amit is a Senior Managing Director of the CVC India team. Prior to joining CVC, he was a Principal at General Atlantic where he spent nine years and led the firm's India investment strategy for internet, business services, software and financial technology. Prior to that Amit worked at 3i, Bill & Melinda Gates Foundation and McKinsey & Co. Amit's previous investment in healthcare includes Citius Tech, a leading healthcare IT services provider and MedExpress, leading chain of urgent care centres. Amit holds an MBA from Wharton and a Bachelor of Technology in Electrical Engineering from IIT Delhi.

Amit is not related to any of the Directors/KMPs of the Company.

6. Allotment of 70,57,195 (Seventy Lakh Fifty-Seven Thousand One Hundred Ninety-Five) equity shares of INR 10 each of the Company, for cash, at a price per share of INR 130 (including share premium of INR 120 per share) upon exercise of 70,57,195 (Seventy Lakh Fifty-Seven Thousand One Hundred Ninety-Five) Series A Warrants by the Investor at a price of INR 130 (Indian Rupees One Hundred Thirty) per warrant at a premium of INR 120 (Indian Rupees One Hundred and Twenty) per share for each warrant.



7. Constitution of the committee of independent directors, pursuant to the regulation 26(6) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, a committee of independent directors (“ICD Committee”) is constituted comprising of the following members of the Board of Directors of the Company as members of ICD Committee: (i) Dr. Sudhakar Rao – Chairman (ii) Mr. Shanker Annaswamy – Member, and (iii) Mrs. Bhushani Kumar - Member.
8. Amendment of the Articles of Association, subject to approval of the shareholders, by restating the same to give effect to the terms of Investment Agreement.

In terms of the Investment Agreement, read with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015), as amended, , the Investor, upon the allotment of shares and warrants and appointment of directors as set out above, is in control of the Company as per the terms of the Investment Agreement with effect from 28 July 2020 and shall be classified as promoter of the Company in accordance with applicable laws on receipt of stock exchange approvals. Dr. B.S. Ajaikumar continues to be in control and to be classified as a promoter of the Company.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For **HealthCare Global Enterprises Limited**



Sunu Manuel
Company Secretary & Compliance Officer